Alteogen and Becton Dickinson to Present "Large-Volume Subcutaneous Injection Technology" at Conference

Animal Study Results of 10mL Subcutaneous Injection Using ALT-B4 Platform Revealed

Alteogen announced on March 30 that it will present the results of its joint research on a large-volume subcutaneous injection device with the U.S. medical device company Becton Dickinson (BD) at an international conference in May.

Alteogen company logo image. Alteogen

The presentation will take place at "PDA Miniverse 2026," which will be held in Dublin, Ireland, from May 21 to 22. The two companies will disclose the results of animal studies in which the hyaluronidase-based platform "ALT-B4" was used to deliver a 10mL volume via subcutaneous injection.

This study compared and evaluated injection speed, required time, and injection site characteristics depending on whether ALT-B4 was applied. The company explained that the technology demonstrates the potential to improve the efficiency of subcutaneous delivery for large-volume biopharmaceuticals.

Alteogen places significance on having validated the scalability of high-volume drug administration by combining BD's drug delivery devices, such as wearable injectors, with its own platform. The company also noted that, as development of high-volume biopharmaceuticals such as monoclonal and bispecific antibodies expands, the importance of related delivery technologies is increasing.

Alteogen has signed multiple agreements with global partners regarding the development of subcutaneous injection formulations based on its Hybrozyme platform. Since the beginning of this year, the company has continued its collaborations with GSK and Biogen, further expanding the range of platform applications.

This content was produced with the assistance of AI translation services.